SHANGHAI – Fast on the heels of a major financing round in November, Beigene Co. has raised $97 million in financing, enough cash to continue to aggressively push its deep pipeline of immuno-oncology candidates in the clinic not only in China, but in global trials as well.
SHANGHAI – Each year investors looking to ride the next big wave of opportunity convene at China's Healthcare Investment Conference to test the waters. This year, the promise of technology to tackle some of China's most complicated health care woes, summed up by the term e-Health, generated the most buzz.
SHANGHAI – China may not be known for innovation, but Generon Corp. Ltd.'s founders decided 12 years ago they were not going to let that stop them from developing a potentially first-in-class biologic: F-652, a recombinant protein containing human interleukin 22 (IL-22).
SHANGHAI – Beigene Co. Ltd. has three candidates currently in phase I trials in Australia and has revealed the science and possible indications behind the cancer compounds: BGB-283, a second generation inhibitor of B-RAF; BGB-290, a poly (ADP-ribose) polymerase (PARP) inhibitor, and BGB-3111, an inhibitor of Bruton tyrosine kinase (BTK).
HONG KONG – In the same week that it started construction of the largest biological manufacturing facility in China, Wuxi Pharmatech Inc. also received a privatization proposal from its founder and chairman.
SHANGHAI – China may not be known for innovation, but Generon Corp. Ltd.'s founders decided 12 years ago they were not going to let that stop them from developing a potentially first-in-class biologic: F-652, a recombinant protein containing human interleukin 22 (IL-22).
HONG KONG – In the same week that it started construction of the largest biological manufacturing facility in China, Wuxi Pharmatech Inc. also received a privatization proposal from its founder and chairman.
SHANGHAI – Beigene Co. Ltd. has three candidates currently in phase I trials in Australia and has revealed the science and possible indications behind the cancer compounds: BGB-283, a second generation inhibitor of B-RAF; BGB-290, a poly (ADP-ribose) polymerase (PARP) inhibitor and BGB-3111 inhibitor of Bruton tyrosine kinase (BTK).
SHANGHAI – Uni-Bio Science Group Ltd. has submitted a new drug application (NDA) to the CFDA for Uni-PTH, a biosimilar of Forteo (teriparatide, Eli Lilly and Co.). The Hong Kong-listed firm is planning for Uni-PTH – a parathyroid hormone 1-34 analogue to treat postmenopausal women with osteoporosis – to be on the market in Mainland China by 2017 at the earliest.
